Sun Pharma, Intrexon partner on synthetic eye drugs
This article was originally published in Scrip
Sun Pharmaceutical Industries and Germantown, Maryland-based Intrexon will develop controllable gene-based therapies for eye diseases in a joint venture that combines Sun Pharma's specialty product development and manufacturing expertise – and the Mumbai, India company's global reach – with Intrexon's synthetic biology technology.
You may also be interested in...
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.